{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:04:29Z","timestamp":1789707869599,"version":"4.0.1"},"reference-count":49,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Non-infectious uveitis (NIU) comprises a group of immune-mediated inflammatory diseases of the uvea that frequently affect people of working age. If inflammation is not controlled promptly, it may lead to permanent structural damage and visual loss. Prolonged corticosteroid use increases the risk of adverse effects. Contemporary treatment aims not only to control inflammation, but also to minimise dependence on corticosteroids. This narrative review examines the efficacy, safety, and place of biological and targeted therapies in the treatment of NIU. Adalimumab is the best-studied biological agent for intermediate, posterior, and panuveitis, as well as for uveitis associated with juvenile idiopathic arthritis. Infliximab has an important role in severe Beh\u00e7et-associated uveitis and occlusive retinal vasculitis. Among the biological therapies with mechanisms of action other than TNF-\u03b1 inhibition, tocilizumab is the best studied, particularly in refractory uveitic macular oedema. Janus kinase inhibitors (JAK inhibitors) are a rapidly developing class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Clinical studies in NIU have shown variable efficacy and indicate their potential as a future therapeutic option. Treatment selection should be individualised and should take into account the anatomical form and severity of uveitis, the presence of systemic disease, macular oedema or occlusive retinal vasculitis, age and comorbidities, and the response to previous therapy. Therapeutic drug monitoring, biomarkers, and quantitative imaging parameters represent promising approaches to treatment personalisation; however, their clinical utility requires validation in prospective studies, and they are not currently part of routine clinical practice in non-infectious uveitis.<\/jats:p>","DOI":"10.3390\/life16091522","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:10:23Z","timestamp":1789373423000},"page":"1522","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological and Targeted Therapy in Non-Infectious Uveitis: Current Evidence and Future Perspectives"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-7143","authenticated-orcid":false,"given":"Vesela Todorova","family":"Mitkova-Hristova","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"},{"name":"Clinic of Ophthalmology, University General Hospital \u201cSt. George\u201d, 4001 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-1488","authenticated-orcid":false,"given":"Marin Anguelov","family":"Atanassov","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"},{"name":"Clinic of Ophthalmology, University General Hospital \u201cSt. George\u201d, 4001 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivaylo Atanasov","family":"Popov","sequence":"additional","affiliation":[{"name":"Department of Propedeutics of Internal Diseases \u201cProf. Dr. Anton Mitov\u201d, Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria"},{"name":"Clinic of Rheumatology, University Multi-Profile Hospital for Active Treatment \u201cKaspela\u201d, Medical University of Plovdiv, 4001 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chauhan, K., and Tyagi, M. (2024). Update on non-infectious uveitis treatment: Anti-TNF-alpha and beyond. Front. Ophthalmol., 4.","DOI":"10.3389\/fopht.2024.1412930"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.preteyeres.2025.101380","article-title":"Immunomodulatory therapy in non-infectious uveitis: Current landscape, gaps, and future directions","volume":"108","author":"Agrawal","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","article-title":"Pathogenesis and current therapies for non-infectious uveitis","volume":"23","author":"Wu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tungsattayathitthan, U., Janetos, T.M., and Goldstein, D.A. (2026). Emerging therapeutic targets in non-infectious uveitis and scleritis. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1846374"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","article-title":"Primary (month-6) outcomes of the STOP-Uveitis study: Evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis","volume":"183","author":"Sepah","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: A multicenter study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ajo.2026.01.037","article-title":"Adalimumab, anakinra, and tocilizumab in patients with noninfectious uveitis: A multicenter randomized controlled trial","volume":"285","author":"Saadoun","year":"2026","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.2147\/JIR.S477708","article-title":"Rituximab in the treatment of non-infectious uveitis: A review","volume":"17","author":"Cao","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12348-021-00252-4","article-title":"Rituximab for non-infectious uveitis and scleritis","volume":"11","author":"Ng","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: The HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4103\/IJO.IJO_61_25","article-title":"JAK-STAT inhibitors in noninfectious uveitis: A review","volume":"73","author":"Pyare","year":"2025","journal-title":"Indian J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II)","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_17","first-page":"76","article-title":"Adalimumab in non-infectious uveitis, towards a real-world optimization: Long-term effectiveness and safety","volume":"15","author":"Gestoso","year":"2025","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","article-title":"Adalimumab in active and inactive non-infectious uveitis: Global results from the VISUAL I and VISUAL II trials","volume":"27","author":"Goto","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ophtha.2025.10.004","article-title":"Adalimumab versus conventional immunosuppression for uveitis (ADVISE) trial","volume":"133","author":"Jabs","year":"2026","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: A double-blind, randomised, placebo-controlled trial of adalimumab in early-onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/acr.23870","article-title":"2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(24)02468-1","article-title":"Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): A multicentre, double-masked, randomised controlled trial","volume":"405","author":"Acharya","year":"2025","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis","volume":"268","author":"Pichi","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chen, H.C., Shunyakova, J., Reddy, A.K., Pandiri, S., and Hassman, L. (2025). Therapeutic drug monitoring and neutralizing anti-drug antibody detection to optimize adalimumab therapy in non-infectious uveitis. Front. Ophthalmol., 5.","DOI":"10.3389\/fopht.2025.1432935"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ard.2026.02.009","article-title":"EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update","volume":"85","author":"Hatemi","year":"2026","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Liu, W., Bai, D., and Kou, L. (2023). Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: A systematic review and meta-analysis. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02987-1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10067-016-3480-x","article-title":"Efficacy and safety of adalimumab in Beh\u00e7et\u2019s disease-related uveitis: A multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower relapse rate with infliximab versus adalimumab in sight-threatening uveitis: A multicenter study of 330 patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: National multicenter study of 177 cases","volume":"71","author":"Mesquida","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116605","DOI":"10.1016\/j.bcp.2024.116605","article-title":"Interleukin-6 in non-infectious uveitis: Biology, signaling and therapeutic implications","volume":"230","author":"Yu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.2147\/JIR.S533011","article-title":"Tocilizumab for non-infectious uveitis: A systematic review","volume":"18","author":"Cao","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): A multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis: Outcomes from the phase 2 SATURN study","volume":"126","author":"Callanan","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with Beh\u00e7et\u2019s disease uveitis: An international, randomized, double-masked, placebo-controlled study and open-label extension","volume":"26","author":"Pavesio","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Vitale, A., Palacios-Olid, J., Caggiano, V., Ragab, G., Hern\u00e1ndez-Rodr\u00edguez, J., Pelegr\u00edn, L., Mej\u00eda-Salgado, G., Zarate-Pinz\u00f3n, L., Gentileschi, S., and Sota, J. (2024). Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: An international multicenter study. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1439338"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41433-025-04065-w","article-title":"The use of Janus kinase inhibitors to treat noninfectious uveitis","volume":"40","author":"Beckman","year":"2026","journal-title":"Eye"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/acr.25644","article-title":"Effectiveness and safety of baricitinib for juvenile idiopathic arthritis-associated uveitis or chronic anterior ANA-positive uveitis: JUVE-BRIGHT","volume":"78","author":"Ramanan","year":"2026","journal-title":"Arthritis Care Res."},{"key":"ref_39","unstructured":"Roivant Sciences (2024). Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis, Roivant Sciences. Roivant Sciences News Release."},{"key":"ref_40","unstructured":"ClinicalTrials.gov (2026). A Study of Brepocitinib in Adults with Active Non-Infectious Non-Anterior Uveitis (CLARITY)."},{"key":"ref_41","unstructured":"US Food and Drug Administration (2021). FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors, FDA Drug Safety Communication."},{"key":"ref_42","unstructured":"Roche (2025). Phase III MEERKAT and SANDCAT Data for Vamikibart in Uveitic Macular Edema, Roche. Roche Media Release."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajo.2025.12.034","article-title":"Dazdotuftide: Novel treatment for noninfectious uveitis with favorable intraocular pressure safety","volume":"284","author":"Chu","year":"2026","journal-title":"Am. J. Ophthalmol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","article-title":"Anti-TNF versus tocilizumab in refractory uveitic cystoid macular edema due to Beh\u00e7et\u2019s disease: A multicenter study","volume":"58","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_47","unstructured":"US Food and Drug Administration (2025). Adalimumab Prescribing Information, FDA Prescribing Information."},{"key":"ref_48","unstructured":"US Food and Drug Administration (2025). Tocilizumab Prescribing Information, FDA Prescribing Information."},{"key":"ref_49","unstructured":"US Food and Drug Administration (2017). Rituximab Prescribing Information: Warnings for Hepatitis B Reactivation and Progressive Multifocal Leukoencephalopathy, FDA Prescribing Information."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1522\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:35:30Z","timestamp":1789706130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091522"],"URL":"https:\/\/doi.org\/10.3390\/life16091522","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}